 Receptors, Progesterone
"Receptors, Progesterone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives.
| Descriptor ID |
D011980
|
| MeSH Number(s) |
D12.776.260.698.750.765 D12.776.826.750.765 D12.776.930.669.750.765
|
| Concept/Terms |
Receptors, Progesterone- Receptors, Progesterone
- Receptors, Progestin
- Progesterone Receptors
- Progestin Receptors
- Progesterone Receptor
- Receptor, Progesterone
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Progesterone".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- DNA-Binding Proteins [D12.776.260]
- Receptors, Cytoplasmic and Nuclear [D12.776.260.698]
- Receptors, Steroid [D12.776.260.698.750]
- Receptors, Progesterone [D12.776.260.698.750.765]
- Receptors, Cytoplasmic and Nuclear [D12.776.826]
- Receptors, Steroid [D12.776.826.750]
- Receptors, Progesterone [D12.776.826.750.765]
- Transcription Factors [D12.776.930]
- Receptors, Cytoplasmic and Nuclear [D12.776.930.669]
- Receptors, Steroid [D12.776.930.669.750]
- Receptors, Progesterone [D12.776.930.669.750.765]
Below are MeSH descriptors whose meaning is more specific than "Receptors, Progesterone".
This graph shows the total number of publications written about "Receptors, Progesterone" by people in this website by year, and whether "Receptors, Progesterone" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 2 | 0 | 2 | | 1981 | 0 | 1 | 1 | | 1983 | 1 | 0 | 1 | | 1985 | 2 | 0 | 2 | | 1986 | 0 | 1 | 1 | | 1988 | 1 | 2 | 3 | | 1994 | 1 | 0 | 1 | | 1995 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2004 | 0 | 2 | 2 | | 2005 | 0 | 4 | 4 | | 2006 | 0 | 3 | 3 | | 2010 | 2 | 0 | 2 | | 2013 | 0 | 1 | 1 | | 2016 | 0 | 1 | 1 | | 2017 | 0 | 2 | 2 | | 2019 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptors, Progesterone" by people in Profiles.
-
Cobleigh M, Yardley DA, Brufsky AM, Rugo HS, Swain SM, Kaufman PA, Tripathy D, Hurvitz SA, O'Shaughnessy J, Mason G, Antao V, Li H, Chu L, Jahanzeb M. Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. Clin Cancer Res. 2020 03 01; 26(5):1105-1113.
-
Kantor O, Barrera E, Kopkash K, Pesce C, Barrera E, Winchester DJ, Yao K. Are we Overtreating Hormone Receptor Positive Breast Cancer with Neoadjuvant Chemotherapy? Role of OncotypeDx® for Hormone Receptor Positive Patients Undergoing Neoadjuvant Chemotherapy. Ann Surg Oncol. 2019 Oct; 26(10):3232-3239.
-
Skowron KJ, Booker K, Cheng C, Creed S, David BP, Lazzara PR, Lian A, Siddiqui Z, Speltz TE, Moore TW. Steroid receptor/coactivator binding inhibitors: An update. Mol Cell Endocrinol. 2019 08 01; 493:110471.
-
Alnajar H, Rosen L, Javidiparsijani S, Al-Ghamdi Y, Gattuso P. Prognostic Markers and Histologic Subtypes in Patients with Meningeal Carcinomatosis in Breast Cancer. Acta Cytol. 2017; 61(2):140-144.
-
Ma H, Ursin G, Xu X, Lee E, Togawa K, Duan L, Lu Y, Malone KE, Marchbanks PA, McDonald JA, Simon MS, Folger SG, Sullivan-Halley J, Deapen DM, Press MF, Bernstein L. Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: a pooled analysis. Breast Cancer Res. 2017 01 13; 19(1):6.
-
Harbhajanka A, Lamzabi I, Syed S, Jain R, Ghai R, Reddy VB, Bitterman P, Gattuso P. Prognostic Value of Coexisting Lobular Carcinoma In Situ With Invasive Lobular Carcinoma. Appl Immunohistochem Mol Morphol. 2016 Nov/Dec; 24(10):738-743.
-
Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L, Jiang G, Miller KD, Gralow JR, Dickler MN, Cobleigh MA, Perez EA, Shenkier TN, Vang Nielsen K, Müller S, Thor A, Sledge GW, Sparano JA, Davidson NE, Badve SS. Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res. 2013 Mar 01; 19(5):1281-9.
-
Yin P, Roqueiro D, Huang L, Owen JK, Xie A, Navarro A, Monsivais D, Coon JS, Kim JJ, Dai Y, Bulun SE. Genome-wide progesterone receptor binding: cell type-specific and shared mechanisms in T47D breast cancer cells and primary leiomyoma cells. PLoS One. 2012; 7(1):e29021.
-
Rao RD, Cobleigh MA, Gray R, Graham ML, Norton L, Martino S, Budd GT, Ingle JN, Wood WC. Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group. Med Oncol. 2011 Dec; 28 Suppl 1:S39-47.
-
Constantinidou A, Jones RL, Reis-Filho JS. Beyond triple-negative breast cancer: the need to define new subtypes. Expert Rev Anticancer Ther. 2010 Aug; 10(8):1197-213.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|